Setrobuvir

TargetMol
Product Code: TAR-T28762
Supplier: TargetMol
CodeSizePrice
TAR-T28762-1mg1mg£263.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-5mg5mg£552.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-1mL1 mL * 10 mM (in DMSO)£694.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-10mg10mg£757.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-25mg25mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-50mg50mg£1,476.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-100mg100mg£1,966.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28762-500mg500mg£3,870.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Setrobuvir, a HCV NS5B polymerase inhibitor, is used potentially for the treatment of HCV infection.
CAS:
1071517-39-9
Formula:
C25H25FN4O6S2
Molecular Weight:
560.62
Pathway:
DNA Damage/DNA Repair|Microbiology/Virology|Cell Cycle/Checkpoint|Proteases/Proteasome
Purity:
0.98
SMILES:
[H][C@@]12CC[C@@]([H])(C1)[C@@]1([H])C(O)=C(C(=O)N(Cc3ccc(F)cc3)[C@@]21[H])C1=NS(=O)(=O)c2cc(NS(C)(=O)=O)ccc2N1
Target:
HCV Protease|SARS-CoV|DNA/RNA Synthesis

References

1. Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, N?jera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T; ANNAPURNA study investigators.. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr;36(4):505-14. doi: 10.1111/liv.12997. PubMed PMID: 26519669. 2. Mallalieu NL, Rahimy MH, Crowley CA, Appleman JR, Smith PF, Freddo JL. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor. Clin Ther. 2014 Dec 1;36(12):2047-2063.e3. doi: 10.1016/j.clinthera.2014.10.002. PubMed PMID: 25456558. 3. Eltahla AA, Tay E, Douglas MW, White PA. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Antimicrob Agents Chemother. 2014 Dec;58(12):7215-24. doi: 10.1128/AAC.03699-14. PubMed PMID: 25246395; PubMed Central PMCID: PMC4249545. 4. De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. PubMed PMID: 24735613.